Global Autoimmune Partnering 2010-2017: Deal trends, players and financials

Friday, April 7, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 6, 2017 /PRNewswire/ -- 

Summary The Global Autoimmune Partnering 2010-2017: Deal trends,

players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies

Read the full report: http://www.reportlinker.com/p04124336/Global-Autoimmune-Partnering-Deal-trends-players-and-financials.html

Description Global

Autoimmune Partnering 2010 to 2017 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Autoimmune partnering deals Financial deal terms for headline, upfront and royalty by stage of development Autoimmune partnering agreement structure Autoimmune partnering contract documents Top Autoimmune deals by value Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, Restless leg syndrome, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Autoimmune deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Autoimmune deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2010. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Global Autoimmune Partnering 2010 to 2017 provides the reader with the following key benefits: - In-depth understanding of Autoimmune deal trends since 2010 - Access Autoimmune deal headline, upfront, milestone and royalty data - Research hundreds of actual contracts between Autoimmune partner companies - Comprehensive access to over 500 links to actual Autoimmune deals entered into by the world's biopharma companies - Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers - Benchmark the key deal terms companies have agreed in previous deals - Identify key terms under which companies partner Autoimmune opportunities Read the full report: http://www.reportlinker.com/p04124336/Global-Autoimmune-Partnering-Deal-trends-players-and-financials.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-autoimmune-partnering-2010-2017-deal-trends-players-and-financials-300436279.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook